Patent · US Active

Compositions and methods for inhibiting expression of Huntingtin gene

US7749978B2 · kind B2 · utility

111Cited by

62References

26Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Dinah Wen-Yee Sah · Boston, US
Philipp Hadwiger · Kulmbach, DE
Ingo Roehl · Memmelsdorf, DE
Birgit Bramlage · Ebikon, CH
Pamela Tan · Kulmbach, DE
Hans-Peter Vornlocher · Bayreuth, DE
David Bumcrot · Belmont, US

Key dates

Filing date	Nov 26, 2007
Grant date	Jul 6, 2010
Priority date	—
Expiry date	Nov 26, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.